Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Biotechnology

Healthcare
$298.71 +1.10%

+$2.89 today

Market cap
$5.98B
Beta
1.04
P/E (TTM)
34.4
EPS (TTM)
$7.72
52W Low $110.00High $268.43

Volume 0.38M

Average 0.22M

LGND Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Ligand Pharmaceuticals IncorporatedNASDAQ: LGND

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation outflow grows to $13.65M

Q2 FY2026 stock-based compensation was $13.65M, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $53.27M.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 24.6 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near $13.65M or moves back toward the trailing-twelve-month quarterly average of $13.32M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$13.65M+28.9% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$53.27M+57.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How LGND compares with its peers on the latest reported figures

  • LGND's LTM Jun 2026 stock-based compensation of $53.27M is the 9th largest of the 10 companies compared; the peer median is $187.88M.
  • Its year-over-year change of +57.8% is the highest of 9, against a peer median of +4.4%.
  • Stock-based compensation amounts to 18.3% of revenue for LGND, versus a peer median of 1.7%.
LGND Competitors Peer median
Stock-Based Compensation for LGND and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABBVAbbVie Inc.LTM Jun 2026$976M +4.5%+12.5%1.5%
PFEPfizer Inc.LTM Jun 2026$947M +14.9%-2.9%1.5%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$553M +4.3%+6.6%1.1%
AMGNAmgen Inc.LTM Jun 2026$492M -3.9%+7.2%1.3%
INCYIncyte CorporationLTM Jun 2026$187.88M -31.7%+9.8%3.2%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$121.89M +50.0%+23.9%13.0%
EXELExelixis, Inc.LTM Jul 2026$112.6M +1.1%+1.6%4.6%
GMABGenmab A/SLTM Jun 2026$71M ——1.7%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$53.27M +57.8%—18.3%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
Peer median (excluding LGND) $187.88M+4.4%+6.9%1.7%

Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income57.14M(33.36M)52.15M(4.03M)124.45M
Depreciation & Amortization50.95M43.39M36.52M35.24M33.78M
Deferred Income Tax(8.62M)20.72M11.7M(15.8M)22.68M
Stock-Based Compensation38.78M60.29M25.74M41.09M0
Change in Working Capital(52.16M)65.68M(34.4M)19.36M(12.67M)
Accounts Receivables(28.62M)55.32M(2.6M)(6.46M)(21.74M)
Inventory(427K)12.06M(10.87M)9.62M4.99M
Accounts Payables(1.17M)(3.34M)(4.7M)05.88M
Other Working Capital(21.96M)1.64M(16.23M)16.2M(1.8M)
Other Non-Cash Items(7.29M)(18.87M)(42.14M)21.2M(118.89M)
Operating Cash Flow78.8M137.85M49.58M97.05M49.36M
Capital Expenditures(8.76M)(17.92M)(53.85M)(19.64M)(452K)
Acquisitions (Net)494K(750K)(25.65M)(172.19M)(8.09M)
Purchases of Investments(181.33M)(51.23M)(126.76M)(226.38M)(730.86M)
Sales of Investments221.34M234.39M194.17M269.62M377.28M
Other Investing Activities(1.22M)(868K)(49.91M)(12.89M)(4.34M)
Investing Cash Flow30.52M163.62M(11.68M)(143.66M)(377.32M)
Debt Repayment(146.01M)(260.8M)(76.9M)(25K)338.11M
Common Stock Issued33.76M3.23M22.45M37.14M114.89M
Common Stock Repurchased(18.45M)000(15M)
Dividends Paid00000
Other Financing Activities(7.07M)(18.42M)(5.5M)60.03M(9.77M)
Financing Cash Flow(137.76M)(275.99M)(59.95M)97.14M428.22M
Effect of Forex Changes000(1.17M)2.36M
Net Change in Cash(28.44M)25.48M(22.05M)49.35M102.62M
Free Cash Flow70.04M119.93M(4.27M)77.41M48.91M

Ligand Pharmaceuticals Incorporated

NASDAQ:LGND

Intrinsic Alpha fair value

Locked

Current Price

$298.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.